^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    SPINK1 (Serine peptidase inhibitor, kazal type 1)

    i
    Other names: SPINK1, Serine peptidase inhibitor, kazal type 1, Pancreatic secretory trypsin inhibitor, Tumor-associated trypsin inhibitor, PSTI
    1d
    Single-Cell Insights into Cisplatin Resistance Mechanisms in Bladder Cancer Tumor Microenvironment. (PubMed, J Biol Chem)
    Moreover, resistant tumor cells enhanced macrophage tolerance to cisplatin via the MIF axis, an effect that was reversed by pharmacological MIF inhibition. Collectively, this integrated single-cell and experimental study reveals critical resistant cell subpopulations, metabolic reprogramming features, and intercellular communication networks driving cisplatin resistance in BC, highlighting potential molecular targets for therapeutic intervention and drug development.
    Journal
    |
    SPINK1 (Serine peptidase inhibitor, kazal type 1)
    |
    cisplatin
    9d
    Discovering Hereditary Risk Through Surveillance: A Prospective Genetic Analysis of Individuals With Familial Pancreatic Cancer. (PubMed, United European Gastroenterol J)
    Integrating germline testing into surveillance redefines the management of familial PC. It uncovers hereditary susceptibility beyond classical criteria and supports cascade testing. PC also arises in mutation-negative HRI. #NCT05724992.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase) • PALB2 (Partner and localizer of BRCA2) • BRCA (Breast cancer early onset) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • MUTYH (MutY homolog) • SPINK1 (Serine peptidase inhibitor, kazal type 1) • CTRC (Chymotrypsin C)
    2ms
    Exacerbated salmonellosis in poly(ADP-ribose) polymerase 14-deficient mice. (PubMed, Microbiol Spectr)
    Yet, the mechanistic basis and, more importantly, the physiological relevance have largely remained elusive. Our study with the systemic Parp14-deficient mice provides compelling in vivo evidence that Parp14 is an integral part of the physiological response to S. Typhimurium infection.
    Preclinical • Journal
    |
    PARP1 (Poly(ADP-Ribose) Polymerase 1) • APOA1 (Apolipoprotein A-I) • SPINK1 (Serine peptidase inhibitor, kazal type 1)
    2ms
    Single-Cell and Bulk RNA Sequencing Reveal SPINK1 and TIMP1 as Epithelial Cell Marker Genes Linked to Colorectal Cancer Survival and Tumor Immune Microenvironment Profiles. (PubMed, Int J Mol Sci)
    EMGs have prognostic value in CRC, with SPINK1 and TIMP1 as independent survival predictors. Distinct immune patterns support integrating EMGs with immune profiling for improved risk stratification and personalized treatment.
    Journal
    |
    CD4 (CD4 Molecule) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • SPINK1 (Serine peptidase inhibitor, kazal type 1)
    2ms
    Decreased Incidence of Acute Pancreatitis in Finland with Biliary Etiology Predominant in Initial Episodes: A Population-Based Study. (PubMed, Dig Dis Sci)
    The total incidence of AP in Pirkanmaa, Finland, was 59.1 per 100,000, and first-episode AP 42.9 per 100,000 - lower than historically reported and comparable to other Western countries. Biliary etiology was most common in first episodes, indicating that alcohol is no longer the predominant etiology of AP in the study area in Finland.
    Journal
    |
    SPINK1 (Serine peptidase inhibitor, kazal type 1)
    2ms
    Mapping Molecular Diversity in Prostate Cancer With a Combined Multiplex IHC and RNA-ISH Assay. (PubMed, Prostate)
    This dual IHC and dual RNA-ISH approach represents a novel and reliable platform for multiplex detection of key prostate cancer biomarkers on a single slide. The method offers significant advantages for molecular classification, tissue-based biomarker validation, and comprehensive evaluation of tumor heterogeneity in translational and diagnostic research.
    Journal
    |
    ETV1 (ETS Variant Transcription Factor 1) • SPINK1 (Serine peptidase inhibitor, kazal type 1) • ETV4 (ETS Variant Transcription Factor 4)
    3ms
    Dual tissue mRNA and serum protein signatures improve risk stratification in hepatocellular carcinoma. (PubMed, NPJ Precis Oncol)
    High-risk HCC responded poorly to sorafenib and transarterial chemoembolization (TACE) but sensitively to agent ABT-263 in silico, in vitro, and in vivo experiments. Interpretability analysis revealed consistent biomarker contributions in both signatures. Conclusively, the dual signatures show promise for HCC risk stratification, pending external validation.
    Journal
    |
    SPINK1 (Serine peptidase inhibitor, kazal type 1) • AKR1B10 (Aldo-Keto Reductase Family 1 Member B10)
    |
    sorafenib • navitoclax (ABT 263)
    3ms
    TRPV6-related pancreatitis: natural history and the impact of the pancreas-specific deletion on pancreatitis in mice. (PubMed, J Gastroenterol)
    Functionally impaired TRPV6 variants significantly influenced the clinical outcomes of chronic pancreatitis. TRPV6 in pancreatic acinar cells might play a protective role against pancreatitis in mice.
    Preclinical • Journal
    |
    TRPV6 (Transient Receptor Potential Cation Channel Subfamily V Member 6) • PDX1 (Pancreatic And Duodenal Homeobox 1) • PRSS1 (Serine Protease 1) • SPINK1 (Serine peptidase inhibitor, kazal type 1)
    3ms
    SPINK1-Driven cellular heterogeneity and interaction Networks in intrahepatic cholangiocarcinoma revealed by integrated multi-omics analysis. (PubMed, J Adv Res)
    Our findings uncover a novel SPINK1-CCL20-LAMs axis that orchestrates immune recruitment and metabolic reprogramming in ICC. SPINK1 facilitates tumor growth by establishing a glutamine-rich microenvironment via LAMs. These insights highlight SPINK1 as a potential therapeutic target and prognostic biomarker in ICC.
    Journal
    |
    SLC1A5 (Solute Carrier Family 1 Member 5) • CCL20 (C-C Motif Chemokine Ligand 20) • SPINK1 (Serine peptidase inhibitor, kazal type 1)
    4ms
    Integration of Single-cell and bulk RNA sequencing data uncovers lymphatic metastasis-related prognostic genes and a predictive model in bladder cancer. (PubMed, Sci Rep)
    Functional enrichment analysis indicated that the high-risk group predominantly activated extracellular matrix (ECM) receptor interactions and the complement pathway, while the low-risk group was primarily associated with carbohydrate metabolism pathways. This study provides insights into the tumor heterogeneity and immune microenvironment of BLCA, introduces a high-precision prognostic model, and establishes a novel theoretical basis for personalized BLCA treatment.
    Journal
    |
    HES1 (Hes Family BHLH Transcription Factor 1) • SPINK1 (Serine peptidase inhibitor, kazal type 1)
    4ms
    Comparison of clinical features and pancreatic cancer risk between genetic mutations associated versus alcohol associated chronic pancreatitis. (PubMed, Pancreatology)
    GCP shows distinct trajectories and an elevated early pancreatic cancer risk, particularly in SPINK1 gene mutation carriers, supporting genotype-stratified surveillance.
    Journal
    |
    PRSS1 (Serine Protease 1) • SPINK1 (Serine peptidase inhibitor, kazal type 1)
    4ms
    CTTN overexpression in HNSCC inhibits Anoikis-apoptosis. (PubMed, Sci Rep)
    Furthermore, we found that inhibiting the apoptosis-related gene CTTN suppresses the anti-apoptotic capacity of HNSCC. Results from HNSCC-PDOs suggest that CTTN may represent a key target for HNSCC invasion and treatment.
    Journal
    |
    TTN (Titin) • SPP1 (Secreted Phosphoprotein 1) • PLK1 (Polo Like Kinase 1) • MAPK1 (Mitogen-activated protein kinase 1) • SLCO1B3 (Solute carrier organic anion transporter family member 1B3) • CEACAM1 (CEA Cell Adhesion Molecule 1) • SFRP1 (Secreted frizzled related protein 1) • SPINK1 (Serine peptidase inhibitor, kazal type 1) • CTTN (Cortactin) • MAD2L1 (Mitotic Arrest Deficient 2 Like 1) • MAPK11 (Mitogen-Activated Protein Kinase 11) • PIK3R2 (Phosphoinositide-3-Kinase Regulatory Subunit 2 ) • PLAU (Plasminogen Activator) • PTK2 (Protein Tyrosine Kinase 2) • SPHK1 (Sphingosine Kinase 1)